Universita' Campus Bio-medico Di Roma
- Address
- lock Available on a paid plan
Cardiovascular Diseases Research
At Universita' Campus Bio-medico Di Roma in Rome, the clinical trial activity is centered on cardiovascular diseases, with a focused effort on understanding and preventing myocardial injury in people hospitalized with pneumonia. The studies are designed to assess whether a potential add-on therapy can help protect the heart while patients are being treated for infection.
- Testing a new supportive therapy aimed at reducing myocardial injury in patients with pneumonia
- Evaluating the safety and effectiveness of a treatment approach in a hospitalized population
- Exploring the link between severe respiratory illness and heart-related complications
This research area reflects a close intersection between cardiology and infectious disease care, with the goal of improving outcomes for patients at risk of cardiac damage during respiratory illness.
Myocardial Injury Prevention Studies
The site is also conducting trials focused specifically on preventing myocardial injury in the setting of pneumonia. These studies aim to determine whether an additional treatment can offer heart protection for hospitalized patients and support safer recovery during acute illness.
- Assessing whether a candidate therapy may help prevent heart injury during pneumonia
- Studying treatment effectiveness in reducing cardiac complications
- Supporting better management of patients with overlapping cardiovascular and respiratory risks
With 51 investigators involved across 5 clinical trials, the research program shows a strong collaborative effort within the Department of Cardiovascular Diseases to address a clinically important complication of infection.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 24 therapeutic areas and 15 of 359 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 327 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 77 by active trials.
- 1AstraZeneca AB9active
lock +76 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB20trials
lock +44 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universita' Campus Bio-medico Di Roma
lock Showing 1 of 255 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors | Cogent Biosciences Inc. | Phase III | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 359 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 15 | Unknown | 2018-04-04 | 2026-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.